Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Meng Lan

Showing results (101-110 of 173) with videos related to

Pageof 18
Sort By:
Viral Immunology|April 23, 2016
Low Ratio of Treg to Th17 Cells After 36 Weeks of Telbivudine Therapy Predict HBeAg SeroconversionMeng-Lan Wang, Qiao-Ling Zhou, En-Qiang Chen, et al.
Saudi Journal of Gastroenterology : Official Journal of the Saudi Gastroenterology Association|October 20, 2020
Clinical features of Epstein-Barr virus in the intestinal mucosa and blood of patients with inflammatory bowel diseaseJin-Qiu Zhou, Li Zeng, Qiao Zhang, et al.
Molecular Diversity|July 19, 2025
Design, synthesis, and biological evaluation of aminopyrazine-based ATR/HDACs dual inhibitorsYing-Hui Yuan, Chen-Chen Wang, Ji-Long Duan, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|March 30, 2023
Research progress of indole-fused derivatives as allosteric modulators: Opportunities for drug developmentMeng-Lan Luo, Qian Zhao, Xiang-Hong He, et al.
Journal of Viral Hepatitis|February 13, 2020
Optimal drug administration manner would rescue partial virological response in chronic hepatitis B patients with entecavir or tenofovir treatmentYa-Chao Tao, Meng-Lan Wang, Dong-Mei Zhang, et al.
The Journal of Organic Chemistry|November 6, 2024
Copper-Catalyzed Radical Sulfonylation: Divergent Construction of C(sp<sup>3</sup>)-Sulfonyl Bonds with SulfonylhydrazonesShan Yu, Jie Lei, Jia Xu, et al.
Journal of Medical Virology|October 15, 2019
Tenofovir monotherapy versus tenofovir plus entecavir combination therapy in HBeAg-positive chronic hepatitis patients with partial virological response to entecavirYong-Hong Wang, Juan Liao, Dong-Mei Zhang, et al.
Environmental Science & Technology|March 7, 2025
Rationally Fabricated Ce-Mn@ZrO<sub>2</sub>-SO<sub>4</sub><sup>2-</sup> Catalyst Boosts the Efficient Destruction of Chlorobenzene with SO<sub>2</sub> Impurity: Synergy of Surface SO<sub>4</sub><sup>2-</sup> and Acidic SitesYukun Sun, Shuai Xu, Bo Bai, et al.
Radiation Oncology (London, England)|June 19, 2022
Current status of neoadjuvant therapy for locally advanced rectal cancer in Wuhan Union Hospital Cancer CenterMeng-Lan Zhai, Fang-Yuan Zhang, Jin-Ru Yang, et al.
Frontiers in Microbiology|July 11, 2022
Serum Pregenomic RNA Combined With Hepatitis B Core-Related Antigen Helps Predict the Risk of Virological Relapse After Discontinuation of Nucleos(t)ide Analogs in Patients With Chronic Hepatitis BFa-Da Wang, Jing Zhou, Lan-Qing Li, et al.
Pageof 18

Showing results (101-110 of 173) with videos related to

Sort By:
Pageof 18
Viral Immunology|April 23, 2016
Low Ratio of Treg to Th17 Cells After 36 Weeks of Telbivudine Therapy Predict HBeAg SeroconversionMeng-Lan Wang, Qiao-Ling Zhou, En-Qiang Chen, et al.
Saudi Journal of Gastroenterology : Official Journal of the Saudi Gastroenterology Association|October 20, 2020
Clinical features of Epstein-Barr virus in the intestinal mucosa and blood of patients with inflammatory bowel diseaseJin-Qiu Zhou, Li Zeng, Qiao Zhang, et al.
Molecular Diversity|July 19, 2025
Design, synthesis, and biological evaluation of aminopyrazine-based ATR/HDACs dual inhibitorsYing-Hui Yuan, Chen-Chen Wang, Ji-Long Duan, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|March 30, 2023
Research progress of indole-fused derivatives as allosteric modulators: Opportunities for drug developmentMeng-Lan Luo, Qian Zhao, Xiang-Hong He, et al.
Journal of Viral Hepatitis|February 13, 2020
Optimal drug administration manner would rescue partial virological response in chronic hepatitis B patients with entecavir or tenofovir treatmentYa-Chao Tao, Meng-Lan Wang, Dong-Mei Zhang, et al.
The Journal of Organic Chemistry|November 6, 2024
Copper-Catalyzed Radical Sulfonylation: Divergent Construction of C(sp<sup>3</sup>)-Sulfonyl Bonds with SulfonylhydrazonesShan Yu, Jie Lei, Jia Xu, et al.
Journal of Medical Virology|October 15, 2019
Tenofovir monotherapy versus tenofovir plus entecavir combination therapy in HBeAg-positive chronic hepatitis patients with partial virological response to entecavirYong-Hong Wang, Juan Liao, Dong-Mei Zhang, et al.
Environmental Science & Technology|March 7, 2025
Rationally Fabricated Ce-Mn@ZrO<sub>2</sub>-SO<sub>4</sub><sup>2-</sup> Catalyst Boosts the Efficient Destruction of Chlorobenzene with SO<sub>2</sub> Impurity: Synergy of Surface SO<sub>4</sub><sup>2-</sup> and Acidic SitesYukun Sun, Shuai Xu, Bo Bai, et al.
Radiation Oncology (London, England)|June 19, 2022
Current status of neoadjuvant therapy for locally advanced rectal cancer in Wuhan Union Hospital Cancer CenterMeng-Lan Zhai, Fang-Yuan Zhang, Jin-Ru Yang, et al.
Frontiers in Microbiology|July 11, 2022
Serum Pregenomic RNA Combined With Hepatitis B Core-Related Antigen Helps Predict the Risk of Virological Relapse After Discontinuation of Nucleos(t)ide Analogs in Patients With Chronic Hepatitis BFa-Da Wang, Jing Zhou, Lan-Qing Li, et al.
Pageof 18